Neurocrine Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	705.5	478.6	341.3	249.7	154.5	89.6
Depreciation & Amortization	47.3	30.1	27.1	21.3	15.6	10.9
Stock-Based Compensation	234.5	217.9	195.5	194.3	173.1	134.2
Other Adjustments	51.7	184.9	50.7	-103.6	63.6	5.1
Change in Receivables	-259.6	-210.5	-39.8	-89.3	-162.2	-28.4
Changes in Inventories	-17.9	-15.3	-19.1	5.4	-2.6	-2.5
Changes in Accounts Payable	109.5	160.2	43.4	49	114.6	56.8
Changes in Income Taxes Payable	25.6	-18.8	50.3	91.6	-	-
Changes in Other Operating Activities	-22.5	-44.4	-54	-28.5	-17.2	-9.2
Operating Cash Flow	898.1	782.7	595.4	389.9	339.4	256.5
Operating Cash Flow Growth	58.31%	31.46%	52.71%	14.88%	32.32%	12.25%
Capital Expenditures	-27.7	-34	-38.2	-28.3	-16.5	-23.4
Purchases of Investments	-1,588	-1,320	-1,056	-1,411	-628.9	-804.7
Proceeds from Sale of Investments	3,020	1,089	967.5	972.4	511	697.9
Cash Acquisitions	-	-	-	-	-42.7	-
Proceeds from Business Divestments	63.2	-	-	-	-	-
Investing Cash Flow	-891.2	-264.4	-126.8	-467.1	-177.1	-130.2
Long-Term Debt Repaid	-	-	-308.8	-	-279	-0.1
Net Long-Term Debt Issued (Repaid)	-	-	-308.8	-	-279	-0.1
Issuance of Common Stock	191.3	129.4	122.1	65.3	44.7	27.5
Repurchase of Common Stock	-66	-167.7	-300	-	-	-
Net Common Stock Issued (Repurchased)	125.3	-38.3	-177.9	65.3	44.7	27.5
Other Financing Activities	-58.4	-	-	-	-	-
Financing Cash Flow	60.2	-38.3	-486.7	65.3	-234.3	27.4
Foreign Exchange Rate Adjustments	-0.2	-	-	0.3	-1.3	-
Net Cash Flow	66.9	480	-18.1	-11.6	-73.3	153.7
Free Cash Flow	870.4	748.7	557.2	361.6	322.9	233.1
Free Cash Flow Growth	64.63%	34.37%	54.09%	11.98%	38.52%	7.12%
FCF Margin	25.80%	26.17%	23.66%	19.16%	21.69%	20.56%
Free Cash Flow Per Share	8.41	7.30	5.37	3.58	3.26	2.38
Levered Free Cash Flow	819.8	556.4	42	360.2	-30.6	122.1
Unlevered Free Cash Flow	710.7	497.85	410.14	299.15	273.75	123.17

SEC Filings: 10-K · 10-Q